[CAS NO. 1228585-88-3] Vesatolimod (GS-9620)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1228585-88-3]
Store
Catalog
SLK-S7221
Brand
Selleck
CAS
1228585-88-3
DESCRIPTION [1228585-88-3]
Overview
| MDL | MFCD25372045 |
|---|---|
| Molecular Weight | 410.51 |
| Molecular Formula | C22H30N6O2 |
| SMILES | O=C1NC2=C(N)N=C(OCCCC)N=C2N(CC3=CC=CC(CN4CCCC4)=C3)C1 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4360 mL | 12.1800 mL | 24.3599 mL |
| 5 mM | 0.4872 mL | 2.4360 mL | 4.8720 mL |
| 10 mM | 0.2436 mL | 1.2180 mL | 2.4360 mL |
| 50 mM | - | - | - |
Description
Vesatolimod (GS-9620) is a potent and selective orally active small molecule agonist of .
Targets
| TLR7 [1] |
In vitro
GS-9620 potently inhibited viral replication in peripheral blood mononuclear cells(PBMCs), particularly when added 24 to 48 hours prior to HIV infection (EC50= 27 nM). Depletion of pDCs, but not other immune cell subsets from PBMC cultures, suppressed GS-9620 antiviral activity.
In vivo
Short-term oral administration of GS-9620 provides long-term suppression of serum and liver HBV DNA. GS-9620 administration induces production of IFN-α and other cytokines and chemokines, and activates ISGs, natural killer cells, and lymphocyte subsets. Its treatment reduces viral DNA, Serum levels of HB surface antigen, HB e antigen and numbers of HBV antigen-positive hepatocytes while hepatocyte apoptosis increases. Currently, GS-9620 is under clinical evaluation for treating chronic HBV infection and for reducing latent reservoirs in virally-suppressed HIV-infected patients.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.